Literature DB >> 19194192

Risk factors for the development of obesity in children surviving ALL and NHL.

Inessa Gofman1, Jonathan Ducore.   

Abstract

We investigated obesity [body mass index (BMI) >95th percentile] and being heavy (BMI >85th percentile) in 95 children in first remission more than 2 years after treatment for acute lymphoblastic leukemia or non-Hodgkin lymphoma seen at our institution. Height, weight and BMI at diagnosis, end of treatment and follow-up, and blood pressure at diagnosis were adjusted by z-score for age and sex. At follow-up, obesity and overweight were not more prevalent than in the general population. Median BMI z-scores rose significantly between diagnosis (0.38) and treatment end (0.62) but not during follow-up (0.70). Median weight z-scores rose significantly during both periods (diagnosis 0.23, treatment end 0.49, and follow-up 0.68). Median height z-scores were 0.51, 0.14, and 0.16 for the same 3 time points, respectively. Repeated measures, multivariate logistic regression identified Hispanic ethnicity, younger age at diagnosis, and a positive age:weight interaction as being associated with obesity and being heavy at follow-up. There was no association with diagnosis, sex, age alone, radiation dose or field, metabolic diagnosis in patient/family, height z-score at diagnosis, duration of treatment, and systolic or diastolic blood pressure. Obesity and overweight were a combination of weight gain and height loss during treatment although weight continued to increase after treatment. We did not identify disease-related parameters associated with these effects.

Entities:  

Mesh:

Year:  2009        PMID: 19194192     DOI: 10.1097/MPH.0b013e31818c0120

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  8 in total

1.  Survivors of standard risk acute lymphoblastic leukemia do not have increased risk for overweight and obesity compared to non-cancer peers: a report from the Children's Oncology Group.

Authors:  Susan J Lindemulder; Linda C Stork; Bruce Bostrom; Xiaomin Lu; Meenakshi Devidas; Stephen Hunger; Joseph P Neglia; Nina S Kadan-Lottick
Journal:  Pediatr Blood Cancer       Date:  2015-02-07       Impact factor: 3.167

2.  Prevalence and Predictors of Overweight and Obesity Among a Multiethnic Population of Pediatric Acute Lymphoblastic Leukemia Survivors: A Cross-Sectional Assessment.

Authors:  Austin L Brown; Philip J Lupo; Heather E Danysh; Mehmet F Okcu; Michael E Scheurer; Kala Y Kamdar
Journal:  J Pediatr Hematol Oncol       Date:  2016-08       Impact factor: 1.289

3.  Body mass index and blood pressure changes over the course of treatment of pediatric acute lymphoblastic leukemia.

Authors:  Adam J Esbenshade; Jill H Simmons; Tatsuki Koyama; Elizabeth Koehler; James A Whitlock; Debra L Friedman
Journal:  Pediatr Blood Cancer       Date:  2011-03       Impact factor: 3.167

Review 4.  Late effects of childhood leukemia therapy.

Authors:  Joy M Fulbright; Sripriya Raman; Wendy S McClellan; Keith J August
Journal:  Curr Hematol Malig Rep       Date:  2011-09       Impact factor: 3.952

Review 5.  Energy balance: an overview with emphasis on children.

Authors:  Charmaine S Tam; Eric Ravussin
Journal:  Pediatr Blood Cancer       Date:  2011-10-20       Impact factor: 3.167

6.  Cardiovascular Risk Factors after Childhood Cancer Treatment Are Independent of the FTO Gene Polymorphism?

Authors:  Małgorzata Sawicka-Żukowska; Maryna Krawczuk-Rybak; Paweł Bernatowicz; Katarzyna Muszyńska-Rosłan; Jerzy Konstantynowicz; Włodzimierz Łuczyński
Journal:  Int J Endocrinol       Date:  2018-02-20       Impact factor: 3.257

7.  Association of Serum Leptin Level with Obesity in Children with Acute Lymphoblastic Leukemia.

Authors:  S Zareifar; S Shorafa; S Haghpanah; Z Karamizadeh; R Adelian
Journal:  Iran J Ped Hematol Oncol       Date:  2015-07-20

8.  Evaluation of Metabolic Syndrome and Related Factors in Children Affected by Acute Lymphoblastic Leukemia.

Authors:  Soheila Zareifar; Sezaneh Haghpanah; Eslam Shorafa; Nader Shakibazad; Zohreh Karamizadeh
Journal:  Indian J Med Paediatr Oncol       Date:  2017 Apr-Jun
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.